

1 **Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected**  
2 **impacts of policy alternatives: A mathematical modeling study**

3  
4 Yiran E Liu, MSc<sup>1,2</sup>, Yasmine Mabene, BSc<sup>2</sup>, Sergio Camelo, MSc<sup>3</sup>, Zulma Vanessa Rueda,  
5 PhD<sup>4,5</sup>, Daniele Maria Pelissari, PhD<sup>6</sup>, Fernanda Dockhorn Costa Johansen, MD<sup>6</sup>, Moises A  
6 Huaman, MD<sup>7</sup>, Tatiana Avalos-Cruz, MD<sup>8</sup>, Valentina A Alarcón, MD<sup>8</sup>, Lawrence M Ladutke,  
7 PhD<sup>9</sup>, Prof. Marcelo Bergman, PhD<sup>10</sup>, Prof. Ted Cohen, DPH<sup>11</sup>, Prof. Jeremy D Goldhaber-  
8 Fiebert, PhD<sup>12,13</sup>, Julio Croda, PhD<sup>11,14,15</sup>, Prof. Jason R Andrews, MD<sup>2</sup>

9  
10 <sup>1</sup> Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.

11 <sup>2</sup> Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University,  
12 Stanford, California, USA.

13 <sup>3</sup> Institute for Computational and Mathematical Engineering, Stanford University, Stanford, California,  
14 USA.

15 <sup>4</sup> Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg,  
16 Canada.

17 <sup>5</sup> School of Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia.

18 <sup>6</sup> National Tuberculosis Program, Ministry of Health, Brasília, Brazil.

19 <sup>7</sup> Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of  
20 Medicine, Cincinnati, Ohio, USA.

21 <sup>8</sup> Dirección de Prevención y Control de la Tuberculosis, Ministerio de Salud, Lima, Perú.

22 <sup>9</sup> Amnesty International USA, New York, New York, USA.

23 <sup>10</sup> Center for Latin American Studies on Insecurity and Violence, National University of Tres de Febrero,  
24 Argentina.

25 <sup>11</sup> Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New  
26 Haven, Connecticut, USA.

27 <sup>12</sup> Department of Health Policy, Stanford University, Stanford, California, USA.

28 <sup>13</sup> Center for Health Policy, Freeman Spogli Institute, Stanford University, Stanford, California, USA.

29 <sup>14</sup> Departamento de Clínica Médica, Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil.

30 <sup>15</sup> Fiocruz Mato Grosso do Sul, Campo Grande, Brazil.

31  
32 **Manuscript Word Count:** 4091

33 **Abstract Word Count:** 250

34 **Tables:** 2

35 **Figures:** 4

36 **References:** 37

37  
38 **Correspondence:**

39 Yiran E Liu

40 Stanford University School of Medicine

41 Department of Epidemiology and Population Health

42 300 Pasteur Drive

43 Stanford, California 94305

44 Email: [yiranliu@stanford.edu](mailto:yiranliu@stanford.edu)

45 **ABSTRACT (250 words)**

46

47 **Background**

48 Tuberculosis incidence is increasing in Latin America, where the incarcerated population has  
49 nearly quadrupled since 1990. The full impact of incarceration on the tuberculosis epidemic,  
50 accounting for effects beyond prisons, has never been quantified.

51

52 **Methods**

53 We calibrated dynamic compartmental transmission models to historical and contemporary data  
54 from Argentina, Brazil, Colombia, El Salvador, Mexico, and Peru, which comprise  
55 approximately 80% of the region's incarcerated population and tuberculosis burden. Using  
56 historical counterfactual scenarios, we estimated the transmission population attributable fraction  
57 (tPAF) for incarceration and the excess population-level burden attributable to increasing  
58 incarceration prevalence since 1990. We additionally projected the impact of alternative  
59 incarceration policies on future population tuberculosis incidence.

60

61 **Findings**

62 Population tuberculosis incidence in 2019 was 29.4% (95% UI, 23.9-36.8) higher than expected  
63 without the rise in incarceration since 1990, corresponding to 34,393 (95% UI, 28,295-42,579)  
64 excess incident cases across countries. The incarceration tPAF in 2019 was 27.2% (95% UI,  
65 20.9-35.8), exceeding estimates for other risk factors like HIV, alcohol use disorder, and  
66 undernutrition. Compared to a scenario where incarceration rates remain stable at current levels,  
67 a gradual 50% reduction in prison admissions and duration of incarceration by 2034 would  
68 reduce population tuberculosis incidence by over 10% in all countries except Mexico.

69

70 **Interpretation**

71 The historical rise in incarceration in Latin America has resulted in a large excess tuberculosis  
72 burden that has been under-recognized to-date. International health agencies, ministries of justice,  
73 and national tuberculosis programs should collaborate to address this health crisis with  
74 comprehensive strategies, including decarceration.

75

76 **Funding**

77 National Institutes of Health

78

79 **Research in context**

80

81 **Evidence before this study**

82 We searched PubMed for studies on tuberculosis in prisons in Latin America, using the search  
83 terms (“tuberculosis”) AND (“prisons” OR “incarceration”) AND (“Latin America” OR  
84 “Argentina” OR “Brazil” OR “Colombia” OR “El Salvador” OR “Mexico” OR “Peru”),  
85 published in any language. Previous studies have identified a high risk of tuberculosis in prisons  
86 in Latin America, finding that notifications in prisons are increasing and account for a growing  
87 proportion of all cases in the region. Other national or sub-national studies have found elevated  
88 tuberculosis risk among formerly incarcerated individuals and transmission chains spanning  
89 prisons and communities. However, the full contribution of incarceration to the broader  
90 tuberculosis epidemic in Latin America—accounting for historical incarceration trends, under-  
91 detection in prisons, and “spillover” effects into communities—has never been quantified.  
92 Furthermore, previous studies have evaluated biomedical interventions in prisons; the regional  
93 impact of alternative incarceration policies on future population tuberculosis incidence is  
94 unknown.

95

96 **Added value of this study**

97 Here we quantify the full contribution of incarceration to the tuberculosis epidemic in Latin  
98 America. Our model captures the dynamic nature of incarceration, incorporating historical and  
99 contemporary data sources to account for varying prison turnover rates and mechanisms  
100 underlying historical incarceration growth. By modeling the population with incarceration  
101 history, we estimate the true size of the ever-exposed population, which across the six countries  
102 is over 11 times the size of the population within prison at any one time. We identify the settings  
103 where excess cases occur and compare our results to crude estimates based on notifications in  
104 prisons. We show, across six countries with diverse carceral contexts and tuberculosis  
105 epidemiology, that incarceration is a leading driver on par with other major tuberculosis risk  
106 factors, a role that has been under-recognized to date. Finally, we demonstrate the potential  
107 impact of alternative incarceration policies in reducing future tuberculosis burden in carceral  
108 settings and the general population.

109

110 **Implications of all the available evidence**

111 To date the true impact of incarceration on the tuberculosis epidemic across the region has been  
112 underestimated due to a narrow focus on disease occurring during incarceration. In light of the  
113 substantial excess tuberculosis burden attributable to incarceration, interventions targeting  
114 incarceration can have outsized effects on the broader tuberculosis epidemic in Latin America—  
115 much greater than previously appreciated. These interventions should include not only strategies  
116 to reduce tuberculosis risk among currently and formerly incarcerated individuals, but also  
117 efforts to end mass incarceration.

## 118 INTRODUCTION

119 Globally, 10.6 million people developed tuberculosis in 2022<sup>1</sup>. While global tuberculosis  
120 incidence has decreased by 8.7% since 2015, in Latin America, tuberculosis incidence increased  
121 by 19% over the same period, highlighting the urgent need to address key tuberculosis drivers in  
122 the region.

123  
124 In Latin America, the incarcerated population has nearly quadrupled over the last thirty years, the  
125 most rapid growth of any region in the world<sup>2</sup>. Persons deprived of liberty (PDL), who may  
126 already face elevated risk of tuberculosis prior to incarceration, are further exposed to prison  
127 conditions that foster transmission and disease progression, including overcrowding, poor  
128 ventilation, malnourishment, and limited access to health care<sup>3</sup>. Together these factors contribute  
129 to tuberculosis rates that, in South America, are 26 times higher among PDL than in the general  
130 population<sup>4</sup>.

131  
132 Recognizing the crisis of tuberculosis in prisons, the Pan-American Health Organization (PAHO)  
133 began requesting data from member states on case notifications occurring among PDL. Between  
134 2014 and 2019, the percent of all notified tuberculosis cases in the region occurring among PDL  
135 increased from 6.6% to 9.4%<sup>3,5</sup>. While alarmingly high, this figure underestimates the  
136 tuberculosis burden attributable to incarceration, for several reasons. First, the case detection  
137 ratio is lower in prisons than in the general population<sup>5</sup>. Second, individuals who acquire  
138 infection in prison often do not progress to tuberculosis disease until after release. Indeed,  
139 previous studies showed that formerly incarcerated individuals had elevated rates of tuberculosis  
140 for up to seven years following release from prison<sup>6,7</sup>. As notifications databases do not record  
141 information on incarceration history, these cases are not currently attributed to incarceration<sup>8</sup>.  
142 Finally, infections acquired in prisons, including among people who work in or visit prisons, can  
143 spread in the community. Accordingly, genomic epidemiologic studies have identified  
144 tuberculosis transmission chains that span prisons and communities<sup>9-13</sup>. Therefore, existing  
145 studies that focus on tuberculosis occurring in prisons overlook the role of incarceration as a  
146 population-level tuberculosis driver.

147  
148 Understanding the full contribution of incarceration to the worsening tuberculosis epidemic in  
149 Latin America is critical to inform tuberculosis prevention strategies and resource allocation.  
150 Furthermore, the impact of alternative incarceration policies on the tuberculosis epidemic  
151 remains unknown, as previous studies have focused on biomedical interventions. In this study,  
152 we use mathematical modeling to quantify the population-level burden of tuberculosis  
153 attributable to incarceration in six countries: Argentina, Brazil, Colombia, El Salvador, Mexico,  
154 and Peru. Specifically, we hypothesize that the rise in incarceration since 1990 has produced a  
155 growing excess tuberculosis burden and hindered tuberculosis progress in the region. We  
156 additionally simulate alternative incarceration policies and project their impact on future  
157 population tuberculosis incidence.

## 158 159 METHODS

### 160 *Setting*

161 We selected countries in Latin America, defined as Mexico, Central America, and South America,  
162 based on data availability and to represent regional heterogeneity in incarceration and  
163 tuberculosis trends (**Figure 1**). Together, the six included countries represent 82.4% of the

164 region's incarcerated population, 79.7% of total tuberculosis notifications, and 80.1% of  
165 tuberculosis notifications in prisons in 2018.

166  
167 *Data sources*

168 We collected data on incarceration prevalence, prison entries or releases, and recidivism from  
169 each country's penitentiary department or census agency via published reports and information  
170 requests (**Table S1, Appendix**). We also referenced reports and articles published by researchers,  
171 international agencies, and journalists. Population estimates and projections were obtained from  
172 World Population Prospects. Population-wide tuberculosis notifications and incidence estimates  
173 were retrieved from the WHO Global Tuberculosis Report<sup>1</sup>. Notifications and incidence  
174 estimates for PDL were sourced from PAHO and a recent study<sup>5</sup> (**Table S2**).

175  
176 *Model development and calibration*

177 We developed a deterministic, meta-population compartmental model to simulate incarceration  
178 and tuberculosis transmission (**Figure S1**). The model includes a simple representation of  
179 tuberculosis natural history across five compartments: susceptible, early latent, late latent,  
180 infectious, and recovered. These compartments are replicated across four population strata,  
181 which individuals traverse via incarceration and release: never incarcerated, currently  
182 incarcerated, recent history of incarceration, and distant history of incarceration. We distinguish  
183 between recent and distant incarceration history to account for the elevated risk of recidivism,  
184 tuberculosis, and mortality in the early period post-release<sup>6,7,14</sup>. The model does not include HIV,  
185 drug resistance, gender/sex, or age structure and excludes children aged 14 years and under who  
186 are assumed to not be at risk of incarceration. We assume that higher tuberculosis risk in prisons  
187 results from higher effective contact rates, higher disease progression rates, and lower diagnosis  
188 rates compared to outside prison. We include low levels of mixing between incarcerated and non-  
189 incarcerated individuals to represent interactions with prison staff and visitors.

190  
191 We fit the model independently for each country to incarceration and tuberculosis data from  
192 1990 to 2023. Yearly calibration targets included incarceration prevalence, prison entries  
193 (admissions), and recidivism, as well as total and within-prison tuberculosis incidence and  
194 notification rates (**Tables S1-S2**). We accounted for uncertainty by sampling from distributions  
195 for calibration targets and for a subset of parameters that were fixed during calibration (**Tables**  
196 **S3-S4**). For each sample of calibration targets and fixed parameters, we then ran optimization  
197 algorithms to calibrate the remaining parameters, obtaining at least 1000 fitted parameter sets per  
198 country (**Figure S4**).

199  
200 For time-varying parameters, we let the model reach equilibrium with baseline values and then  
201 applied rates of change starting in the year 1990. Changes in incarceration prevalence over time  
202 were achieved through changes in prison entry and release rates; changes in tuberculosis  
203 incidence and notification rates were achieved through changes in effective contact rates and  
204 diagnosis rates (**Table S5, Figure S5**). We also accounted for COVID-19 pandemic-related  
205 changes (**Table S6**).

206  
207 Details on model specification, assumptions, calibration, and validation are provided in the  
208 **Appendix**.

209

210 *Excess burden estimates*

211 For each country, we quantified the excess population-level tuberculosis incidence attributable to  
212 the rise in incarceration prevalence since 1990 by simulating a counterfactual scenario where  
213 incarceration prevalence and dynamics remained stable at 1990 levels. To operationalize this, for  
214 each set of fitted parameters, we re-ran the model from 1990, with time-dependent changes in  
215 prison entry and release rates turned off. We also eliminated time-dependent changes in the  
216 effective contact rate within prison, which we assumed to be linked to growing prison  
217 populations. We then calculated the excess burden as the relative and absolute difference in  
218 population tuberculosis incidence between the observed and counterfactual scenarios. We report  
219 excess burden estimates in 2019 and 2022 but use 2019 for our main estimates due to COVID-  
220 19-related uncertainty. We also analyze where excess incident cases arose—i.e., where  
221 individuals progressed or relapsed to infectious tuberculosis disease—and where cases were  
222 diagnosed and notified.

223

224 *Sensitivity analyses and meta-modeling*

225 We performed five sensitivity analyses varying key assumptions around natural history,  
226 differences across strata, changes over time, and mixing. We additionally conducted linear  
227 regression meta-modeling using a multi-level model to identify parameters associated with  
228 variation in excess burden estimates<sup>15</sup>. The **Appendix** includes details on sensitivity analyses and  
229 meta-modeling.

230

231 *Transmission population attributable fraction (tPAF)*

232 To estimate the tPAF for incarceration among individuals aged 15 and older, we simulated a  
233 scenario where incarceration prevalence was gradually reduced to zero by 2009 (**Appendix**).  
234 After ten years of no new exposure to incarceration, we calculated the tPAF for incident cases in  
235 2019 as follows<sup>16</sup>:

236

$$tPAF = \frac{Pop.TB\ incidence_{observed} - Pop.TB\ incidence_{incarceration\ eliminated}}{Pop.TB\ incidence_{observed}}$$

237

238 We compared our estimates of the tPAF for incarceration with WHO's country-specific estimates  
239 of the fraction of all incident cases attributable to each of five major tuberculosis risk factors in  
240 2019. We note that risk factors may be overlapping, and that WHO's estimates apply to varying  
241 age groups: undernutrition, all ages; HIV, all ages; alcohol use disorders, age  $\geq 15$ ; smoking, age  
242  $\geq 15$ ; diabetes, age  $\geq 18$ . For diabetes, the PAF is reported as a fraction of all cases among  
243 individuals age  $\geq 15$ , rather than a true PAF, and therefore may be an overestimate.

244

245 *Future policy scenarios*

246 We simulated various incarceration scenarios over a ten-year period (2024–2034) and estimated  
247 their impacts on future population tuberculosis incidence. Under the reference or “stable”  
248 scenario, prison entry rates and average duration of incarceration remain constant. Under the  
249 “continue trends” scenario, entry rates and duration undergo the same relative net change  
250 between 2024 and 2034 as over the prior ten years. The decarceration scenarios involve gradual  
251 25% or 50% reductions in entry rates, duration, or both by 2034. We computed the percent  
252 difference in projected population tuberculosis incidence in 2034 under each scenario compared  
253 to that expected under the stable scenario.



254  
255 In El Salvador, the prison population has nearly tripled since March 2022 under a continued state  
256 of emergency<sup>17</sup>. We estimate the excess population TB incidence in 2024 attributable to the  
257 recent state of emergency by simulating a counterfactual scenario without the observed rise in  
258 incarceration prevalence since March 2022. We additionally simulated the following future  
259 scenarios from 2024-2034: 1) continuation of current entry and release rates under the state of  
260 emergency; 2) passive abatement through entry and release rates gradually returning to their pre-  
261 emergency levels by 2034; and 3-5) active cessation of the state of emergency by 2025 and  
262 reversion of incarceration prevalence to its approximate pre-emergency level in ten, five, or two  
263 years (i.e., by 2034, 2029, or 2026, respectively), with continued decarceration thereafter.  
264 Reversion of incarceration prevalence to pre-emergency levels under scenarios 3-5 is achieved  
265 through entry and release rates changing promptly by 2025. Rather than comparing to a reference  
266 scenario, we computed the percent change in population tuberculosis incidence in 2034 under  
267 each scenario compared to 2021. Methods for future projections are detailed in the **Appendix**.

268  
269 *Role of the funding source*  
270 The funders had no role in study design, data collection, data analysis, data interpretation,  
271 writing, or decision to submit the paper for publication.

272  
273 **RESULTS**  
274 Argentina, Brazil, Colombia, El Salvador, Mexico, and Peru exhibited wide variability in the  
275 population-wide and within-prison burden of tuberculosis between 1990 and 2019 (**Table 1**). In  
276 2019, the tuberculosis notification rate in prisons was a median 28.7 (IQR 13.1-31.6) times the  
277 population-wide notification rate (**Table 1**). Calibrated effective contact rates, disease  
278 progression rates, and diagnosis rates in prison were a median 6.8 (IQR 2.5-11.9), 2.3 (2.0-2.9),  
279 and 0.55 (0.44-0.59) times those in the community, respectively (**Table S7**).

280  
281 Between 1990 and 2019, the prevalence of incarceration among the population aged 15 and older  
282 more than doubled in all countries except Mexico, reaching a median 360 (IQR 317 to 439) per  
283 100,000 in 2019 across the six countries (**Table 1**). This historical rise was driven by an increase  
284 in prison entry rates (Argentina and Brazil), an increase in average duration of incarceration  
285 (Peru), or both (El Salvador, Colombia, Mexico) (**Table S8**). By 2019, the average duration of  
286 incarceration ranged from 1.3 years (95% UI 1.1-1.6) in Brazil to 6.0 years (4.8-8.0) in El  
287 Salvador (**Table 1**). Further, the percent of the prison population with prior incarceration history  
288 ranged from 18% (95% UI 12-22) in El Salvador to 52% (41-59) in Brazil. Such differences in  
289 incarceration dynamics contribute to the heterogeneity in community prevalence of incarceration  
290 history among the population age 15 and older, which ranged from 1.3% (95% UI 1.0-1.7) in  
291 Argentina to 6.0% (4.7-7.6) in Mexico (**Table 1**). Across all six countries in 2019, while 1.3  
292 million people were incarcerated at any given time, we estimate that an additional 13.4 million  
293 (95% UI 11.4-15.7 million) people were living with incarceration history.

294  
295 Compared to a counterfactual scenario where incarceration prevalence remained constant since  
296 1990, the observed rise in incarceration prevalence since 1990 resulted in an estimated 34,393  
297 (95% UI, 28,295-42,579) excess incident cases in 2019 across the six countries (**Figure 2A-B**,  
298 **Table 2**). The excess population tuberculosis incidence in 2019 varied widely across countries,  
299 ranging from 6% or 1.3 (95% UI 0.8-2.1) cases per 100,000 person-years in Mexico to 134% or

300 32.2 (25.5-41.3) cases per 100,000 person-years in El Salvador (**Table 2**). Estimates for the year  
301 2022 were comparable (**Table S9**). Sensitivity analyses varying several assumptions did not  
302 substantively change our results (**Figure S9**).

303  
304 The burden of excess incident cases that arose (i.e., progressed to disease or relapsed) in prisons  
305 in 2019 exceeded that of excess cases *diagnosed* within prisons by 81%, ranging from an  
306 additional 10% in El Salvador to 102% in Colombia (**Figure 2C**). Furthermore, a considerable  
307 fraction of the excess burden in 2019 was comprised of incident cases arising among formerly  
308 incarcerated individuals, particularly in countries with shorter average duration of incarceration  
309 (**Figure 2C**). For instance, the percent of excess cases arising in the community among formerly  
310 incarcerated individuals was 34% (95% UI 24-45) in Argentina, 34% (26-42) in Brazil, and 26%  
311 (16-36) Mexico (**Table S11**). In all countries, estimated tuberculosis incidence rates among  
312 individuals with recent or incarceration history were much higher than population-wide  
313 incidence rates (**Figure S10, Table S12**).

314  
315 Collectively across countries, incarceration was the leading determinant compared to other key  
316 tuberculosis risk factors, accounting for an estimated 27.2% (95% UI, 20.9-35.8) of incident  
317 cases in 2019 among the population aged 15 and older. The country-specific tPAF of  
318 incarceration in 2019 reached 58.1% (95% UI, 51.6-64.1) in El Salvador, 36.9% (29.5-45.1) in  
319 Brazil, 23.3% (16.7-34.4) in Peru, 21.8% (14.1-34.7) in Colombia, 8.4% (6.0-18.6) in Argentina,  
320 and 7.5% (4.8-11.6) in Mexico (**Table 2**). Despite this variability, the country-specific tPAF for  
321 incarceration was consistently greater than or commensurate with PAFs for other major risk  
322 factors (**Figure 3**). Moreover, our median tPAF estimate was 1.3 to 6.3 times the percent of all  
323 tuberculosis notifications occurring in prisons in 2019 (**Figure 3**).

324  
325 We projected the impact of future incarceration policies, implemented from 2024 to 2034, on  
326 population tuberculosis incidence in 2034. Future projections for El Salvador are described  
327 below. For all other countries, projected incarceration prevalence in 2034 under each scenario is  
328 shown in **Figure 4A** and **Table S13**. If recent incarceration trends continue, projected population  
329 tuberculosis incidence in 2034 would be slightly (<3%) higher in Peru, Argentina, and Mexico,  
330 and slightly lower in Colombia and Brazil (**Figure 4B**). More active decarceration  
331 interventions—for instance, a 50% decrease in prison entry rates and duration of incarceration—  
332 could reduce population tuberculosis incidence in 2034 by an estimated 28.9% (95% UI 22.0-  
333 36.7) in Brazil, 16.4% (11.4-23.3) in Peru, 13.7% (8.9-21.3) in Colombia, 10.3% (7.1-16.9) in  
334 Argentina, and 3.0% (1.3-5.7) in Mexico.

335  
336 In El Salvador, we project that population TB incidence in 2024 is 2.1 (95% UI 1.8-2.4) times as  
337 high as expected without the recent state of emergency, corresponding to 2,444 (95% UI 1,562-  
338 3,245) excess incident cases in 2024 (**Figure S11**). Maintaining the state of emergency for ten  
339 years is projected to increase population tuberculosis incidence in 2034 by 112% (95% UI 63-  
340 176) compared to pre-emergency in 2021 (**Figure 4C**). A gradual, passive abatement of the state  
341 of emergency would still increase population tuberculosis incidence in 2034 by a projected 39%  
342 (95% UI 13-72). In contrast, prompt and active cessation of the state of emergency and reversion  
343 of incarceration prevalence to approximate pre-emergency levels by 2034 could restore  
344 population tuberculosis incidence in 2034 to its approximate rate in 2021. More decisive actions  
345 to revert pre-emergency incarceration prevalence in two or five years and continue further



346 decarceration thereafter could reduce population tuberculosis incidence in 2034 by as much as 34%  
347 (95% UI 25-42) compared to 2021.

348

## 349 **DISCUSSION**

350 Across six Latin American countries, more than 34,000 incident cases in 2019 can be attributed  
351 to the rise in incarceration since 1990. Collectively in these countries, incarceration accounts for  
352 an estimated 27.2% (95% UI, 20.9-35.8) of incident cases in 2019 among individuals aged 15  
353 and older, a far greater fraction than any other determinant. Against the backdrop of the region's  
354 alarming increase in tuberculosis incidence over the last decade, we project that policies to  
355 reduce incarceration prevalence may considerably reduce future population tuberculosis  
356 incidence. Together, our results implicate incarceration as the leading population-level driver of  
357 the tuberculosis epidemic in Latin America. In addition to improving prison conditions and  
358 implementing biomedical interventions in prisons, criminal legal reforms and development of  
359 non-carceral alternatives will be critical to re-ignite progress towards tuberculosis elimination.

360

361 Our results elucidate the harmful impacts of decades of punitive policies on the tuberculosis  
362 epidemic in the region. Beginning in the 1990s, amidst rising crime and public support for  
363 "tough-on-crime" initiatives, governments in Latin America expanded police and prosecutorial  
364 activity, criminalized new acts, and imposed harsher sentences, including for minor offenses<sup>18,19</sup>.  
365 Consequently, prison populations surged, largely comprised of individuals detained for property-  
366 and drug-related offenses<sup>18,20</sup>. Meanwhile, inadequate investments in the penitentiary system led  
367 to severe overcrowding, inhumane living conditions, deficient health care, corruption among  
368 staff, uprisings, and self-governance<sup>18,21</sup>. Today, the incarceration rate in Latin America is twice  
369 the global rate and higher than all other regions except North America<sup>2</sup>. Criminologists argue that  
370 prisons have been ineffective and even counterproductive in curbing crime in the region<sup>18,21</sup>.  
371 Instead, they have created new challenges, including a worsening crisis of tuberculosis in prisons.

372

373 In the present study, we show that the scope and magnitude of this crisis is even larger than  
374 previously recognized. To date, research and policy guidance has focused on tuberculosis  
375 occurring within prisons<sup>3,22-25</sup>. However, unlike other TB risk factors, incarceration is highly  
376 dynamic. The constant flow of people who are newly incarcerated and released yields a much  
377 larger population ever exposed to the high-risk carceral environment, which we estimate across  
378 the six countries is over 11 times the size of the population in prison at any given time. By  
379 accounting for this phenomenon and its interplay with the variable latent period of tuberculosis,  
380 we obtained attributable burden estimates that far exceeded crude, static estimates based on  
381 notifications in prisons. Of note, most of the difference was due to under-detection in prisons and  
382 progression to disease following release, rather than onward transmission. Thus, while traditional  
383 PAF estimates for other TB determinants may also be underestimated due to not accounting for  
384 onward transmission, incarceration is particularly subject to under-recognition by conventional  
385 approaches that do not account for its dynamic nature. Policy guidance and future research  
386 should recognize incarceration as a tuberculosis driver and social determinant with effects that  
387 transcend prison walls.

388

389 We also demonstrate the potential impact of alternative incarceration policies on the tuberculosis  
390 epidemic in the region. For instance, policies that decrease prison admissions and duration by 50%  
391 could reduce future population tuberculosis incidence by more than 10% in Brazil, Peru,

392 Colombia, and Argentina, countries which encompass the vast majority of the region's  
393 tuberculosis burden. In El Salvador, which already had an exorbitant tPAF for incarceration prior  
394 to 2022, the state of emergency is projected to have catastrophic consequences for tuberculosis.  
395 We predict that swift, resolute termination of the state of emergency could enable a return to pre-  
396 emergency incidence by 2034, and that further decarceration can recover, at least in part, a  
397 decade of lost opportunity for tuberculosis progress. Such measures have precedent in  
398 Kazakhstan, where KNCV and Penal Reform International co-led comprehensive efforts to  
399 address tuberculosis in prisons, integrating biomedical interventions with decriminalization  
400 reforms, implementation of alternatives to incarceration, and improvements in prison  
401 conditions<sup>26</sup>. Following expansion of the program in 2000, incarceration prevalence decreased by  
402 70% and with it, the rate of tuberculosis in prisons by 90%<sup>27</sup>. Therefore, decarceration  
403 interventions, especially if coupled with biomedical interventions and efforts to improve prison  
404 conditions, have substantial potential to accelerate progress towards 2035 End TB strategy  
405 targets.

406  
407 Our estimates of the tuberculosis burden attributable to incarceration vary greatly across the six  
408 countries included, correlating with incarceration prevalence and country-specific disparities in  
409 tuberculosis risk between prisons and the general population. Between-country variation in  
410 where excess cases arise can also be attributed to distinct carceral dynamics across countries. For  
411 instance, in countries with a longer average duration of incarceration, like El Salvador and Peru,  
412 our model predicts that the vast majority of excess incident cases occur within prisons<sup>5</sup>.  
413 Conversely, in countries with a shorter average duration of incarceration, i.e., Brazil and Mexico,  
414 a greater proportion of excess incident cases occur in the community after prison release.  
415 Therefore, it is crucial to consider incarceration dynamics and changing carceral policies in  
416 identifying optimal intervention strategies. These insights may generalize to other countries and  
417 regions. Specifically, in most other settings with lower incarceration rates and less disparity in  
418 tuberculosis rates between prisons and the general population, incarceration may play a lesser  
419 role in the tuberculosis epidemic. Nonetheless, in all settings, the true incarceration-attributable  
420 tuberculosis burden likely exceeds crude estimates based on tuberculosis occurring within  
421 prisons, especially where prison turnover rates are high.

422  
423 In response to this public health crisis, bold and decisive investments and actions are needed.  
424 First, international health agencies and national tuberculosis programs must improve reporting of  
425 incarceration as a structural determinant of tuberculosis. This includes collecting information on  
426 incarceration history in case notifications databases and including current and past incarceration  
427 as a key risk factor in WHO's Global Tuberculosis Report<sup>8</sup>. Given the stigma and discrimination  
428 faced by individuals with incarceration history, procedures for collecting this information in a  
429 sensitive manner should be developed alongside stakeholders with lived experience of  
430 incarceration<sup>28</sup>. Second, effective strategies to prevent, detect, and treat tuberculosis in  
431 incarcerated and formerly incarcerated individuals must be identified, incorporated in national  
432 guidelines, and implemented at scale<sup>29,30</sup>. While existing research has focused on prison-based  
433 interventions, future work should expand to include formerly incarcerated individuals and their  
434 community contacts.

435  
436 Lastly, and equally as important, governments must implement structural reforms to reduce the  
437 prison population. While our study focused on tuberculosis, incarceration exposure has been

438 linked to other adverse health outcomes<sup>14,31,32</sup>. Therefore, decarceration strategies, especially in  
439 conjunction with efforts to transform conditions of confinement, have the potential to both  
440 accelerate tuberculosis progress and improve population health at large. Currently, political will  
441 and public support for such measures remain low. However, calls are growing for governments to  
442 improve prison conditions, decriminalize minor offenses, reduce pre-trial detention, and develop  
443 restorative justice-based alternatives to incarceration, with several initiatives underway across  
444 the region<sup>18,20,21,33-36</sup>.

445  
446 Our study has several limitations. First, for four of six countries—all except Brazil and  
447 Colombia—empirical prison-based active case-finding studies were unavailable, so prison  
448 incidence estimates for model calibration were based on a regional case detection ratio. For these  
449 countries, findings should be viewed as estimates within a plausible range of uncertainty. Second,  
450 deterministic compartmental models are unable to capture the full range of complexity in real-  
451 world phenomena. The extent to which we were able to incorporate complexity in our model was  
452 constrained by inadequate data to inform model parameters and assumptions. For instance, our  
453 model did not account for age, gender/sex, socioeconomic status, HIV, heterogeneity in duration  
454 of incarceration, heterogeneity in infectiousness, or MDR-TB, which is less common in prisons  
455 in the Americas than in other regions<sup>37</sup>. Accounting for HIV or MDR-TB, which may be  
456 exacerbated in prisons, may increase estimates of the incarceration-attributable burden<sup>12</sup>.  
457 Accounting for other factors like age or socioeconomic inequities that affect mixing and  
458 tuberculosis risk may result in lower estimates for incarceration<sup>24</sup>. Moreover, we had little to no  
459 data to inform mixing assumptions or stratum-specific parameters for formerly incarcerated  
460 individuals. In these cases of insufficient data, we used wide parameter uncertainty distributions  
461 and varied our assumptions in sensitivity analyses, with our findings generally remaining robust.  
462 However, the dearth of reliable, publicly accessible data on incarceration and tuberculosis must  
463 be urgently addressed.

464  
465 Next, our future projections are subject to great uncertainty, including uncertainty around how  
466 the COVID-19 pandemic has affected and will continue to affect tuberculosis and incarceration.  
467 We were unable to model specific policies or reforms (i.e., decriminalization of drug use) due to  
468 insufficient data. Our future simulations also do not include changes in any other dimension  
469 aside from prison entry and release rates, such as improvements in prison conditions or scale-up  
470 of biomedical interventions. Generally, our historical counterfactual and future policy  
471 simulations are simplistic, modifying incarceration in isolation from what is inevitably an  
472 intricate web of upstream and downstream social, economic, political, and institutional forces  
473 that themselves also affect population health and tuberculosis. Nonetheless, our findings  
474 underscore the substantial potential for criminal legal reforms to reduce tuberculosis burden in  
475 Latin America, impacts which could be enhanced by additional prison- and community-based  
476 interventions.

477  
478 To date we have failed to appreciate the full extent to which rising incarceration has undermined  
479 tuberculosis control in Latin America. Our estimates of the outsized tuberculosis burden  
480 attributable to incarceration eclipse those of other determinants that currently receive far greater  
481 attention. However, this exceptional excess burden must not be regarded as inevitable. Health  
482 agencies, national tuberculosis programs, ministries of justice, and other key stakeholders should  
483 undertake bold commitments and actions to elevate the prominence of incarceration in national

484 and international strategies for tuberculosis control and elimination, accounting for impacts  
485 beyond prison walls. These strategies should take an integrated health and human rights  
486 approach, combining biomedical interventions and improvements in prison conditions with  
487 actions to enable decarceration. Such measures will be critical to advancing towards regional and  
488 global tuberculosis elimination targets.

489 **Table 1. Incarceration- and tuberculosis-related characteristics by country.** All population-  
 490 wide prevalence estimates are for the population aged 15 and older. Data sources are detailed in  
 491 Tables S1-S2 of the Appendix. For model outputs, medians are shown with 95% uncertainty  
 492 intervals in parentheses.

	Argentina	Brazil	Colombia	El Salvador	Mexico	Peru	Source
Incarcerated population in 1990*	21,016	90,000	32,387	5,982	93,119	17,859	Data
Incarcerated population in 2019	109,405	755,274	123,078	38,114	200,936	95,548	Data
Prison occupancy in 2018 (%) <sup>^</sup>	112	165	146	333	97	219	Data
Prevalence of incarceration per 100,000 in 2019	321	452	316	825	216	399	Data
Percent increase in prevalence of incarceration since 1990	239 (229, 249)	397 (393, 400)	120 (107, 134)	372 (331, 404)	28 (19, 38)	190 (171, 197)	Model
Incarceration growth driven by increasing entry rates and/or duration?	Entry rates	Entry rates	Both	Both	Both	Duration	Model
Average duration of incarceration in 2019 (years)	2.6 (2.2, 3.4)	1.3 (1.1, 1.6)	3.2 (2.7, 3.8)	6.0 (4.8, 8.0)	1.9 (1.6, 2.3)	4.7 (3.9, 5.8)	Model
Within-prison prevalence of incarceration history (%)	30 (21, 37)	52 (41, 59)	21 (15, 27)	18 (12, 22)	25 (17, 32)	25 (18, 32)	Model
Community prevalence of incarceration history (%) <sup>#</sup>	1.3 (1.0, 1.7)	2.8 (2.0, 3.9)	4.2 (3.0, 5.6)	2.9 (2.2, 3.6)	6.0 (4.7, 7.6)	3.5 (2.8, 4.3)	Model
Population-level tuberculosis notifications in 2019	11,446	85,523	14,292	3,009	23,702	31,764	Data
Population tuberculosis notification rate per 100,000 in 2019	25.7	40.5	28.7	47.9	19.0	97.6	Data
Prison tuberculosis notification rate per 100,000 in 2019	214	1303	784	3484	144	2945	Data
Percent of all tuberculosis notifications occurring in prisons in 2019	2.0	11.5	6.8	44.1	1.2	8.9	Data

493 \*Data are from 1992 for Argentina.

494



495 **Table 2. Estimates of population tuberculosis incidence attributable to incarceration in**  
496 **2019.** All estimates are at the population-level among individuals aged 15 and older. Incidence  
497 rate ratios and excess burden estimates were obtained from comparing incident tuberculosis  
498 cases in 2019 between the observed scenario of the historical rise in incarceration and the  
499 counterfactual scenario of no change in incarceration prevalence since 1990. The transmission  
500 population attributable fraction in 2019 was estimated using a scenario where incarceration  
501 prevalence was reduced to zero by 2009. 95% uncertainty intervals are shown in parentheses.  
502

	Incidence rate ratio for observed vs. counterfactual	Excess cases per 100,000 person-years relative to counterfactual	Absolute excess cases relative to counterfactual	Transmission population attributable fraction (%)
Argentina	1.06 (1.04, 1.16)	1.5 (1.0, 3.9)	506 (344, 1344)	8.4 (6.0, 18.6)
Brazil	1.44 (1.32, 1.59)	14.1 (10.9, 18.4)	23497 (18160, 30739)	36.9 (29.5, 45.1)
Colombia	1.23 (1.13, 1.42)	6.0 (3.4, 10.6)	2337 (1338, 4135)	21.8 (14.1, 34.7)
El Salvador	2.34 (2.03, 2.69)	32.2 (25.5, 41.3)	1489 (1178, 1907)	58.1 (51.6, 64.1)
Mexico	1.06 (1.04, 1.09)	1.3 (0.8, 2.1)	1180 (740, 1957)	7.5 (4.8, 11.6)
Peru	1.21 (1.13, 1.34)	20.6 (12.6, 33.0)	4922 (3028, 7899)	23.3 (16.7, 34.4)

503

504 **FIGURE LEGENDS**

505

506 **Figure 1. Geographic, demographic, and epidemiologic heterogeneity among included**  
507 **countries.** Countries included in the analysis are highlighted in color; remaining countries in  
508 Latin America are depicted in grey. Incarceration prevalence refers to the number of people per  
509 100,000 population who are incarcerated at a given point in time. Tuberculosis (TB) notification  
510 rates are per 100,000 person-years. Data on prison tuberculosis notifications are only available  
511 starting in 2000. Latin America includes Mexico, Central America, and South America.

512

513 **Figure 2. Excess population tuberculosis incidence attributable to the rise in incarceration**  
514 **prevalence since 1990.** A) Population tuberculosis incidence per 100,000 person-years under the  
515 observed and counterfactual (no rise in incarceration since 1990) scenarios. Black points  
516 represent population tuberculosis (TB) incidence estimates from the World Health Organization,  
517 which are available beginning in 2000. Solid lines and shaded bands represent the median and 95%  
518 UI respectively. B) Excess population-wide incident tuberculosis cases per 100,000 person-years.  
519 C) Median estimates of excess cases, stratified by population subgroup in which they occurred,  
520 and for incident cases occurring in prison, additionally stratified by whether the disease was  
521 notified or undetected during incarceration. All model results are for the population age 15 and  
522 older.

523

524 **Figure 3. Population attributable fraction (PAF) for incarceration and other tuberculosis**  
525 **risk factors.** Median estimates and uncertainty intervals for the percent of population-level  
526 incident tuberculosis cases in 2019 that can be attributed to each risk factor. The “crude” estimate  
527 of the population attributable fraction for incarceration is based on the percent of all notified  
528 tuberculosis cases occurring in prisons. Estimates for all other risk factors are from the World  
529 Health Organization (WHO). Risk factors are listed in descending order by PAF for each country.  
530 Estimates correspond to different age groups: incarceration, age  $\geq 15$ ; undernutrition, all ages;  
531 HIV, all ages; alcohol, age  $\geq 15$ ; smoking, age  $\geq 15$ ; diabetes, age  $\geq 18$  (see **Methods**).

532

533 **Figure 4. Projected impacts of incarceration-related interventions on future population**  
534 **tuberculosis incidence.** A) Median incarceration prevalence per 100,000 population aged 15 and  
535 older under incarceration scenarios implemented between 2024 and 2034: stable entry and  
536 release rates (reference scenario), continuation of trends from prior ten years, and 25% or 50%  
537 reduction in prison entry rates, duration of incarceration, or both by 2034. The dashed horizontal  
538 line represents incarceration prevalence in 1990. B) Percent difference in population tuberculosis  
539 incidence in 2034 under each incarceration scenario, relative to the reference scenario of stable  
540 entry and release rates. Outliers are not shown. C) Left: Median incarceration prevalence under  
541 each incarceration scenario in El Salvador: continuation of entry and release rates under the state  
542 of emergency, passive abatement through gradual reversion of entry and release rates to pre-  
543 emergency levels by 2034, active cessation and approximate restoration of pre-emergency  
544 incarceration prevalence in ten years, or restoration of pre-emergency prevalence in five years or  
545 two years with continued decarceration thereafter. The dashed horizontal line represents  
546 incarceration prevalence in 1990. Right: Percent change in population TB incidence since 2021  
547 under each scenario.

548

549

550 **Author contributions**

551 YEL and JRA conceived and designed the study. YEL and YM collected data with assistance  
552 from LML. YEL and YM developed and calibrated the incarceration sub-model. YEL developed  
553 and calibrated the primary tuberculosis model, performed analyses, and made tables and figures.  
554 SC, JDGF, and JRA assisted with model development and calibration. JRA, JC, JDGF, and TC  
555 provided guidance on analyses. YEL wrote the first draft of the manuscript. YM and MB  
556 contributed to writing of subsequent drafts. All authors contributed to data interpretation and  
557 critical revision of the manuscript. YEL and YM accessed and verified the underlying data. All  
558 authors approved the final version of the manuscript and agreed to submission.

559

560 **Declaration of interests**

561 We declare no competing interests.

562

563 **Acknowledgments**

564 This study was funded by the National Institutes of Health (grant numbers 5R01AI130058 and  
565 5R01AI149620). YEL is funded by the Stanford Knight Hennessy Scholars Program, the  
566 National Science Foundation Graduate Research Fellowship, and the Gerald J. Lieberman  
567 Fellowship from the Stanford Office of the Vice Provost for Graduate Education. We thank  
568 Edwin Segura, Noah Bullock, Hernán Olaeta, the National Penitentiary and Prison Institute of  
569 Colombia, and Victor Peña Garcia for providing data and useful insights.

570

571 **Data sharing**

572 No individual participant data were collected in this study. Data and code used for modeling are  
573 available at [github.com/yemloo/tb\\_incarc\\_mod](https://github.com/yemloo/tb_incarc_mod).




574 **REFERENCES**

- 575 1. Global Tuberculosis Report 2023: World Health Organization, 2023.
- 576 2. Institute for Crime & Justice Policy Research. World Prison Brief. [prisonstudies.org](https://prisonstudies.org)  
577 (accessed December 3 2023).
- 578 3. Walter KS, Martinez L, Arakaki-Sanchez D, et al. The escalating tuberculosis crisis in  
579 central and South American prisons. *The Lancet* 2021; **397**(10284): 1591-6.
- 580 4. Cords O, Martinez L, Warren JL, et al. Incidence and prevalence of tuberculosis in  
581 incarcerated populations: a systematic review and meta-analysis. *The Lancet Public Health* 2021.
- 582 5. Martinez L, Warren JL, Harries AD, et al. Global, regional, and national estimates of  
583 tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a  
584 systematic analysis. *The Lancet Public Health* 2023; **8**(7): e511-e9.
- 585 6. Mabud TS, de Lourdes Delgado Alves M, Ko AI, et al. Evaluating strategies for control  
586 of tuberculosis in prisons and prevention of spillover into communities: An observational and  
587 modeling study from Brazil. *PLOS Medicine* 2019; **16**(1): e1002737.
- 588 7. Sequera G, Estigarribia-Sanabria G, Aguirre S, et al. Excess tuberculosis risk during and  
589 following incarceration in Paraguay: a retrospective cohort study. *The Lancet Regional Health –*  
590 *Americas*.
- 591 8. Guillermo S, Sarita A, Gladys E, et al. Incarceration and TB: the epidemic beyond prison  
592 walls. *BMJ Global Health* 2024; **9**(2): e014722.
- 593 9. Walter KS, Pereira dos Santos PC, Gonçalves TO, et al. The role of prisons in  
594 disseminating tuberculosis in Brazil: A genomic epidemiology study. *The Lancet Regional*  
595 *Health – Americas* 2022; **9**.
- 596 10. Warren JL, Grandjean L, Moore DAJ, et al. Investigating spillover of multidrug-resistant  
597 tuberculosis from a prison: a spatial and molecular epidemiological analysis. *BMC Medicine*  
598 2018; **16**(1): 122.
- 599 11. Sanabria GE, Sequera G, Aguirre S, et al. Phylogeography and transmission of  
600 *Mycobacterium tuberculosis* spanning prisons and surrounding communities in Paraguay. *Nature*  
601 *Communications* 2023; **14**(1): 303.
- 602 12. Utpatel C, Zavaleta M, Rojas-Bolivar D, et al. Prison as a driver of recent transmissions  
603 of multidrug-resistant tuberculosis in Callao, Peru: a cross-sectional study. *The Lancet Regional*  
604 *Health – Americas*.
- 605 13. Trevisi L, Brooks MB, Becerra MC, et al. Who Transmits Tuberculosis to Whom: A  
606 Cross-Sectional Analysis of a Cohort Study in Lima, Peru. *American Journal of Respiratory and*  
607 *Critical Care Medicine* 2024.
- 608 14. Liu YE, Lemos EF, Gonçalves CCM, et al. All-cause and cause-specific mortality during  
609 and following incarceration in Brazil: A retrospective cohort study. *PLOS Medicine* 2021; **18**(9):  
610 e1003789.
- 611 15. Jalal H, Dowd B, Sainfort F, Kuntz KM. Linear regression metamodeling as a tool to  
612 summarize and present simulation model results. *Med Decis Making* 2013; **33**(7): 880-90.
- 613 16. Mishra S, Baral SD. Rethinking the population attributable fraction for infectious  
614 diseases. *The Lancet Infectious Diseases* 2020; **20**(2): 155-7.
- 615 17. Régimen de excepción. <https://www.asamblea.gob.sv/taxonomy/term/1922> (accessed  
616 February 12 2024).
- 617 18. Bergman M, Fondevila G. Prisons and Crime in Latin America: Cambridge University  
618 Press; 2021.




- 619 19. Hathazy P, Müller M-M. The rebirth of the prison in Latin America: determinants,  
620 regimes and social effects. *Crime, Law and Social Change* 2016; **65**(3): 113-35.
- 621 20. Chaparro Hernández SPC, Catalina. Sobredosis carcelaria y política de drogas en  
622 América Latina 2017. [https://www.dejusticia.org/publication/sobredosis-carcelaria-y-politica-de-](https://www.dejusticia.org/publication/sobredosis-carcelaria-y-politica-de-drogas-en-america-latina/)  
623 [drogas-en-america-latina/](https://www.dejusticia.org/publication/sobredosis-carcelaria-y-politica-de-drogas-en-america-latina/) (accessed June 28, 2024).
- 624 21. InSight Crime. The Prison Dilemma: Latin America's Incubators of Organized  
625 Crime 2017. [https://insightcrime.org/investigations/prison-dilemma-latin-america-incubators-](https://insightcrime.org/investigations/prison-dilemma-latin-america-incubators-organized-crime/)  
626 [organized-crime/](https://insightcrime.org/investigations/prison-dilemma-latin-america-incubators-organized-crime/) (accessed June 28, 2024).
- 627 22. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 2:  
628 Screening - Systematic Screening for Tuberculosis Disease, 2021.
- 629 23. World Health Organization. Tuberculosis in prisons. 2023.  
630 [https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/featured-topics/tb-in-prisons)  
631 [2023/featured-topics/tb-in-prisons.](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023/featured-topics/tb-in-prisons)
- 632 24. Pelissari DM, Diaz-Quijano FA. Impact of incarceration on tuberculosis incidence and its  
633 interaction with income distribution inequality in Brazil. *Transactions of The Royal Society of*  
634 *Tropical Medicine and Hygiene* 2020; **114**(1): 23-30.
- 635 25. Li Y, de Macedo Couto R, Pelissari DM, et al. Excess tuberculosis cases and deaths  
636 following an economic recession in Brazil: an analysis of nationally representative disease  
637 registry data. *The Lancet Global Health* 2022; **10**(10): e1463-e72.
- 638 26. Atabay T, Laticevski V, Vasil'eva TF. Human Rights and Health in Prisons: a review of  
639 strategy and practice: Penal Reform International and Royal Netherlands Tuberculosis  
640 Foundation (KNCV), 2006.
- 641 27. Pak S. Reforming the prison system: focusing on pre-trial detainees. Prison TB Alliance  
642 Meeting. Asuncion, Paraguay; 2024.
- 643 28. Sue K. How to Talk with Patients about Incarceration and Health. *AMA J Ethics* 2017;  
644 **19**(9): 885-93.
- 645 29. Charalambous S, Velen K, Rueda Z, et al. Scaling up evidence-based approaches to  
646 tuberculosis screening in prisons. *The Lancet Public Health* 2023; **8**(4): e305-e10.
- 647 30. Narayan A, Salindri AD, Keshavjee S, et al. Prioritizing persons deprived of liberty in  
648 global guidelines for tuberculosis preventive treatment. *PLOS Medicine* 2023; **20**(10): e1004288.
- 649 31. Silverman-Retana O, Servan-Mori E, Bertozzi SM, Orozco-Nuñez E, Bautista-Arredondo  
650 S, Lopez-Ridaura R. Prison environment and non-communicable chronic disease modifiable risk  
651 factors: length of incarceration trend analysis in Mexico City. *Journal of Epidemiology and*  
652 *Community Health* 2018; **72**(4): 342-8.
- 653 32. Marmolejo L, Barberi D, Bergman M, Espinoza O, Fondevila G. Responding to COVID-  
654 19 in Latin American Prisons: The Cases of Argentina, Chile, Colombia, and Mexico. *Victims &*  
655 *Offenders* 2020; **15**(7-8): 1062-85.
- 656 33. COPLAD. Latin American jurists propose a regional pact to humanize penitentiary  
657 policies 2024. <https://coplad.eu/en/alternative-penalties-workshop-barcelona/> (accessed July 2,  
658 2024).
- 659 34. Brazil National Council of Justice. Training Guide on Alternatives to Imprisonment I:  
660 Postulates, principles and guidelines for the policy of alternatives to imprisonment in Brazil,  
661 2023.
- 662 35. Mahtani N. El modelo 'antiBukele' funciona en Costa Rica. *El País*, 2023.  
663 [https://elpais.com/america-futura/2023-11-13/el-modelo-antibukele-funciona-en-costa-](https://elpais.com/america-futura/2023-11-13/el-modelo-antibukele-funciona-en-costa-rica.html#?rel=mas)  
664 [rica.html#?rel=mas](https://elpais.com/america-futura/2023-11-13/el-modelo-antibukele-funciona-en-costa-rica.html#?rel=mas) (accessed July 2, 2024).




- 665 36. Youngers C. Colombia to Implement Law on Alternatives to Incarceration for Women  
666 Heads of Household2022. [https://www.wola.org/analysis/colombia-law-alternatives-](https://www.wola.org/analysis/colombia-law-alternatives-incarceration-women-heads-household/)  
667 [incarceration-women-heads-household/](https://www.wola.org/analysis/colombia-law-alternatives-incarceration-women-heads-household/) (accessed July 2, 2024).  
668 37. Gygli SM, Loiseau C, Jugheli L, et al. Prisons as ecological drivers of fitness-  
669 compensated multidrug-resistant Mycobacterium tuberculosis. *Nat Med* 2021; **27**(7): 1171-7.  
670



Incarceration Scenario ■ Observed ■ No Change Since 1990



Status of Person with TB ■ In Prison (Notified) ■ In Prison (Undetected) ■ Previously Incarcerated ■ Never Incarcerated



WHO estimates
  Crude estimates based on notifications in prisons
  Modeled estimates for incarceration

